drugset / Trial / NCT01203072

A Phase 2b Study of DU-176b, Prevention of Venous Thromboembolism in Patients After Total Knee Arthroplasty

NCT01203072

Phase 2 Completed 523 enrolled Daiichi Sankyo
RandomizedParallel-groupQuadruple-blindPrevention

Summary

The objective of this study is to assess the efficacy, safety and dose-response relationship of DU-176b compared with placebo for the prevention of venous thromboembolism in patients after elective total knee arthroplasty.

Timeline

Start
2006-07
Primary completion
2007-09
Completion
2008-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Edoxaban Small molecule 5 mg Oral
Subject Edoxaban Small molecule 15 mg Oral
Subject Edoxaban Small molecule 30 mg Oral
Subject Edoxaban Small molecule 60 mg Oral